Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Non-cash Items (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Non-cash Items for 11 consecutive years, with $438919.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items rose 50.83% to $438919.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $438919.0, a 50.83% increase, with the full-year FY2024 number at $378000.0, down 71.3% from a year prior.
  • Non-cash Items was $438919.0 for Q3 2025 at Marker Therapeutics, up from $433178.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $5.3 million in Q2 2022 to a low of $14000.0 in Q3 2022.
  • A 5-year average of $1.4 million and a median of $560929.0 in 2022 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: skyrocketed 8314.29% in 2021, then crashed 99.63% in 2022.
  • Marker Therapeutics' Non-cash Items stood at $4.3 million in 2021, then plummeted by 86.95% to $560929.0 in 2022, then soared by 134.79% to $1.3 million in 2023, then crashed by 71.3% to $378000.0 in 2024, then grew by 16.12% to $438919.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Non-cash Items are $438919.0 (Q3 2025), $433178.0 (Q2 2025), and $411591.0 (Q1 2025).